Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| IntelGenx Technologies Corp | Montelukast VersaFilm - (MONTPARK) | Parkinson's Disease (PD) | Phase 2 | Enrollment Initiation | Buccal | Neurology |
| Intellia Therapeutics Inc. | Lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) - (HAELO) | Hereditary angioedema (HAE) | Phase 3 | Enrollment Conclusion | Intravenous | Genetic Disorder |
| Intellia Therapeutics Inc. | Nexiguran ziclumeran (nex-z, NTLA-2001) - (MAGNITUDE) | Transthyretin amyloidosis (ATTR) | Phase 3 | Clinical Pause | Intravenous | Genetic Disorder |
| Intellia Therapeutics Inc. | Nexiguran Ziclumeran (nex-z) - (MAGNITUDE-2) | Hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) | Phase 3 | Ongoing | Oral | Genetic Disorder |
| Intellia Therapeutics Inc. | Nexiguran ziclumeran (nex-z, NTLA-2001) - (MAGNITUDE) | Transthyretin amyloidosis (ATTR) | Phase 3 | Clinical Pause | Intravenous | Genetic Disorder |
| Intensity Therapeutics Inc. | INT230-6 - (INVINCIBLE-2) | Early stage breast cancer | Phase 2 | Data Released | Intratumoral | Oncology |
| Intensity Therapeutics Inc. | INT230-6 (VINblastine CIsplatin) - (INVINCIBLE-3) | Early-stage presurgical breast cancer | Phase 3 | Looking for Funding | Intratumoral | Oncology |
| Intensity Therapeutics Inc. | INT230-6 in combination with Yervoy | Triple Negative Breast Cancer, Sarcomas, Hepatic Cancers | Phase 2 | Trial Completed | Intratumoral and intravenous | Oncology |
